Immunotherapy of sepsis: Flawed concept or faulty implementation?

Vaccine

Volumn 17, Issue SUPPL. 2, 1999, Pages

  Cross, Alan S ^a   Opal, Steven M ^b   K Bhattacharjee, Apurba ^c   Donta, Sam T ^d   Peduzzi, Peter N ^d   Fürer, Emil ^e   Que, John U ^e   Cryz Jr, Stanley J ^e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d Vet Admin Coop Studies Group   (United States)

^e Berna Biotech AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ENDOTOXIN ANTIBODY; GLYCOLIPID;

ACTIVE IMMUNIZATION; ANTIBODY BLOOD LEVEL; CONFERENCE PAPER; GRAM NEGATIVE SEPSIS; IMMUNOTHERAPY; INFECTION PREVENTION; INTENSIVE CARE; NEUTROPENIA; PASSIVE IMMUNIZATION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; ENDOTOXINS; GRAM-NEGATIVE BACTERIAL INFECTIONS; IMMUNOTHERAPY, ACTIVE; RATS; SEPSIS; TREATMENT OUTCOME;

EID: 0033215450     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00230-3     Document Type: Conference Paper

References (44)

1. Braude A.E., Jones J.L., Douglas H. The behavior of Escherichia coli endotoxin (somatic antigen) during infectious arthritis. J. Immunol. 90:1963;297-312.
2. Braude A.I., Ziegler E.J., McCutchan J.A., Douglas H. Immunization against nosocomial infection. Amer. J. Med. 70:1981;463-466.
3. McCabe W.R. Immunization with R mutants of S. minnesota. Part I: Protection against challenge with heterologous gram-negative bacilli. J. Immunol. 108:1972;601-610.
4. Ziegler E.J., McCutchan J.A., Fierer J., et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307:1982;1225-1230.
5. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J. Infect. Dis. 165:1992;695-701.
6. Prophylactic intravenous immunoglobulin administration of standard immunoglobulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N. Engl. J. Med. 327:1992;234-240.
7. Calandra T., Glauser M.P., Schellekens J., Verhoef J. Swiss-Dutch J5 immunoglobulin study group. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J. Infect. Dis. 158:1988;312-319.
8. Ziegler E.J., Fisher C.J. Jr, Sprung C.L., Straube R.C., Sadoff J.C., Foulke G.E.G., Wortel C.H., Fink M.P., Dellinger R.P., Teng N.N.H., Allen I.E., Berger H.J., Knatterud G.L., LoBuglio A.F., Smith C.R. Treatment of gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 325:1991;429-436.
9. Greenman R.L., Schein R.M.H., Martin M.A., Wenzel R.P., Mac Intyre N.R., Emmanuel G., Chmel H., Kohler R.B., McCarthy M., Plouffe J., Russell J.A. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA. 266:1991;1097-1102.
10. Baumgartner J.D. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect. Dis. Clin. North Am. 5:1991;915-927.
11. Morrison D.C., Dinarello C.A., Munford R.S., Natanson C., Danner R., Pollack M., Spitzer J.J., Ulevitch R.J., Vogel S.N., McSweegan E. Current status of bacterial endotoxin. ASM News. 60:1994;479-484.
12. Cross A.S., Opal S. Therapeutic intervention in sepsis with antibody to endotoxin: is there a future? J. Endotox. Res. 1:1994;57-69.
13. Pollack M., Huang A.I., Prescott R.K., et al. Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J. Clin. Invest. 72:1983;1874-1881.
14. Goldie A.S., Fearon K.C.H., Ross J.A., Barclay R., Jackson R.E., Grant I.S., Ramsay G., Blyth A.S., Howie J.C. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA. 274:1995;172-177.
15. Zinner S.H., McCabe W.R. Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J. Infect. Dis. 133:1976;37-45.
16. Nys M., Damas P., Joassin L., Lamy M. Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome. Ann. Surg. 217:1993;300-306.
17. Schedel I., Dreikhausen U., Nentwig B., Hockenschneider M., Rauthmann D., Balikcioglu S., Coldewey R., Deicher H. Treatment of gram-negative septic shock with an immuno-globulin preparation: a prospective, randomized clinical trial. Crit. Care Med. 9:1991;1104-1113.
18. Fomsgaard A., Baek L., Fomsgaard J.S., Engquist A. Preliminary study on treatment of septic shock patients with antilipopolysaccharide IgG from blood donors. Scand. J. Infect. Dis. 21:1989;697-708.
19. Bhattacharjee A.K., Opal S.M., Palardy J.E., Drabick J.J., Collins H., Taylor R., Cotton A., Cross A.S. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. J. Infect. Dis. 170:1994;622-629.
20. Donta S.T., Peduzzi P., Cross A.S., et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. J. Infect. Dis. 174:1996;537-543.
21. Baumgartner J.D., Glauser M.P., McCutchan J.A., Ziegler E.J., Van Melle G., Klauber M.R., Vogt M., Muehlen E., Luethy R., Chiolero R., Geroulanos S. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 2:1985;59-63.
22. Baumgartner J.D., Heumann D., Calandra T., Glauser M.P. Antibodies to lipopolysaccharide after immunization of humans with the rough mutant Escherichia coli. J. Infect. Dis. 163:1991;769-772.
23. Santosham M., Reid R., Ambrosino D.M., Wolff M.C., Almeido-Hill J., Priehs C., Aspery K.M., Garrett S., Croll L., Foster S., Burge G., Page P., Zacher B., Moxon R., Siber G.R. Prevention of Haemophilus influenzae type B infections in high-risk infants treated with bacterial polysaccharide immune globulin. N. Engl. J. Med. 317:1987;923-929.
24. Cross A.S., Sidberry H., Sadoff J.C. The human antibody response during natural bacteremic infection with gram-negative bacilli against lipopolysaccharide core determinants. J. Infect. Dis. 160:1989;225-236.
25. Bailat S., Heumann D., LeRoy D., Baumgartner J.D., Rietschel E.T., Glauser M.P., Di Padova F. Similarities and disparities between core-specific and O-side chain-specific antilipopoly-saccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice. Infect. Immun. 65:1997;811-814.
26. Baumgartner J.D., Heumann D., Gerain J., Weinbreck P., Grau G.E., Glauser M.P. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor α and interleukin 6: comparison of O side chain-specific antibodies with core LPS antibodies. J. Exp. Med. 171:1990;889-896.
27. Edelman R., Taylor D.N., Wasserman S.S., McClain J.B., Cross A.S., Sadoff J.C., Que J.U., Cryz S.J. Jr. Phase I trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an 8 valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine. 12:1994;1288-1294.
28. McClain JB, Shmuklarsky M, Mereish KA, Que J, Eliasson A, Edelman R, Cryz SJ, Cross AS, Persistence of hyperimmune immunoglobulin directed against Klebsiella and Pseudomonas in normal volunteers and ill patients, submitted.
29. Campbell W.N., Hendrix E., Cryz S.J., Cross A.S. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an 8-valent Pseudomnas O-polysaccharide conjugate vaccine administered to acute trauma victims. Clin. Infect. Dis. 23:1996;179-181.
30. Ertel W., Faist E., Nestle C. Kinetics of interleukin-2 and interleukin-6 synthesis following major mechanical trauma. J. Surg. Res. 48:1990;622-628.
31. Lyons A., Kelly J.L., Rodrick M.L., Mannick J.A., Lederer J.A. Major injury induces increased production of interleukin-10 by cells of the immune system with a negative impact on resistance to infection. Ann. Surg. 226:1997;450-460.
32. Giannoudis P.V., Smith R.M., Banks R.E., Windsor A.C.J., Dickson R.A., Guillou P.J. Stimulation of inflammatory markers after blunt trauma. Brit. J. Surg. 85:1998;986-990.
33. Powderly W.G., Pier G., Markham R.B. In vitro T cell-mediated killing of Pseudomonas aeruginosa. IV. Nonresponsiveness of polysaccharide-immunized BALB/c mice is attributable to vinblastine-sensitive suppressor T cells. J. Immunol. 137:1986;2025-2034.
34. Ehrke M.J., Mihich E., Berd D., Mastrangelo M.J. Effects of anticancer drugs on the immune system in humans. Semin. In. Oncol. 16:1989;230-253.
35. n-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low dose cyclophosphamide. J. Immunother. with Emphasis on Tumor Immunol. 19:1996;309-316.
36. Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA. 273:1995;117-123.
37. Salvo I., de Cian W., Musicco M. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Medicine. 21:1995;S244-S249.
38. DeMaria A. Jr, Johns M.A., Berberich H., McCabe W. Immunization with rough mutants of Salmonella minnesota: initial studies in human subjects. J. Infect. Dis. 158:1988;301-311.
39. Schwartzer T.A., Alcid D.V., Numsuwan V., Gocke D.J. Characterization of the human anti-body response to an Escherichia coli O111:B4 (J5) vaccine. J. Infect. Dis. 158:1988;1135-1136.
40. Lugowski C., Jachymek W., Niedziela T., Rowinski S. Serological characterization of anti-endotoxin sera directed against the conjugates of oligosaccharide core of Escherichia coli type R1, R2, R3, J5 and Salmonella Ra with tetanus toxoid. FEMS Immunol. Med. Microbiol. 16:1996;21-30.
41. Lugowski C., Niedziela T., Jachymek W. Anti-endotoxin antibodies directed against Escherichia coli R1 oligosaccharide core-tetanus toxoid conjugate bind to smooth live bacteria and smooth lipopolysaccharides and attenuate their tumor necrosis factor stimulating activity. FEMS Immunol. Med. Microbiol. 16:1996;31-38.
42. Bhattacharjee A.K., Cross A.S., Opal S.M., et al. New trends in Escherichia coli O111:B4 J5 mutant (Rc Chemotype) vaccine development for use in gram-negative bacillary sepsis. Morrison D.C., Ryan J.L. Novel therapeutic strategies in the treatment of sepsis. 1996;31 Marcel Dekker, New York.
43. Bhattacharjee A.K., Opal S.M., Taylor R., Naso R., Semenuk M., Zollinger W.D., Moran E.E., Young L., Hammack C., Sadoff J.C., Cross A.S. A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc Chemotype) lipopolysaccharide and Neisseria meningitidis Group B outer membrane protein produces protective antibodies against gram-negative bacteremia. J. Infect. Dis. 173:1996;1157-1163.
44. Overbeek B.P., Veringa E.M. Role of antibodies and antibiotics in aerobic gram-negative septicemia: possible synergism between antimicrobial treatment and immunotherapy. Rev. Infect. Dis. 13:1991;751-760.